Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity.
Cloud software for bioinformatics and systems biology is relaunched [...]
The Xerna™ TME Panel is a pan-cancer RNA-based investigational [...]
Biomarker discovery platform will incorporate pan-cancer tumor microenvironment classifier [...]
Machine Learning technology platform to be evaluated for potential [...]
Welcome to Talking Precision Medicine — the podcast in [...]
Cancer trials that stratify patients using biomarkers increase their [...]
Genialis, a computational precision medicine company unraveling complex biology [...]
Genialis, a leader in applied data science for the [...]
Welcome to the Talking Precision Medicine podcast. In this [...]
